Lupin (500257) Q1 25/26 earnings summary

Executive summary

• Achieved double-digit revenue and profit growth in Q1 FY26, with EBITDA margin expanding to 26.6% and net income rising over 52% year-over-year, driven by strong U.S. and India performance and key product launches like tolvaptan with sole exclusivity.

• U.S. business reached its highest revenue since Q4 FY17, led by new launches and a strong respiratory portfolio; India formulations grew 8.6% year-over-year, with chronic therapies comprising about 65% of sales.

• Other developed markets, especially Europe, saw robust growth, with Europe up 28% year-over-year and EMEA sales rising 25%.

• Recent acquisitions, including Renascience Pharma Limited, and business transfers such as the carve-out of the consumer and API R&D businesses, are expected to support future growth.

• Board approved Q1 FY26 results on August 5, 2025, with a limited review by statutory auditors.

Financial highlights

• Q1 FY26 sales were ₹62,683.4 million, up from ₹56,003.3 million in Q1 FY25, with U.S. sales up 24.3%, India up 7.8%, and other developed markets up 17.4%.

• EBITDA increased to ₹16,414 million, up 27.6% year-over-year, with a margin of 26.6%.

• Net income rose to ₹12,214.6 million, a 52% increase year-over-year.

• Gross margin improved to 71.3% from 68.4% a year ago, driven by better product mix and cost efficiencies.

• Net cash stood at INR 1,239 crores as of June 30, 2025.

Outlook and guidance

• Reaffirmed full-year EBITDA margin guidance at 24%-25% and expects strong double-digit top-line growth for FY26, with high single-digit to double-digit growth targeted for FY27.

• Plans to launch 20+ products in India and file 15+ products in the U.S. in FY26, focusing on complex generics and specialty products.

• R&D spend projected at 7.5%-8.7% of sales for FY26.

• Anticipates continued robust performance, though margins may be tempered by higher R&D and lower PLI incentives.

• Recent acquisitions and business transfers are expected to support future growth.